- Initial focus on patient derived TILs in gynaecological cancers
- RemedyBio will collaborate with researchers at Imperial College London
- Combination of approaches for speed to the clinic.
Dublin, Ireland, June 02, 2022 – RemedyBio, a development stage biotech company combining the power of ultra-scale single cell analysis and viable recovery in its Nanoreactor™ platform for discovery and development of effective therapies in immune diseases, today announces a collaborative research project with Imperial College London for a novel tumour infiltrating lymphocyte (TILs) discovery approach and pre-clinical evaluation in gynaecological & other cancers. TILs are showing great promise in the treatment of cancer including those of gynaecological origin, due to their ability to target and kill cancer deposits and their excellent safety profile.
This collaborative project will use RemedyBio’s novel platform for ultra-high throughput therapeutic discovery. This combines millions of parallel single cell analyses to rapidly identify and retrieve individual rare immune cells. This includes activated tumour-derived T-cells that can then be harvested and used for cancer patients as a personalised cell therapy. This platform has the potential to generate advanced yet cost-effective immunotherapies.
“We are very pleased to be working with the talented Imperial team on this exciting project”, said Dr. Colm Galligan, Chief Medical Officer of RemedyBio. “We believe that the combination of the Nanoreactor platform for identification and retrieval of activated and functional TILs, coupled with Imperial’s expertise and translational models, will rapidly allow for development of new therapies for gynaecological cancers where there is a great unmet medical need.”
“RemedyBio unique platform allows us to differentiate the most active patient specific immune cells against cancer allowing us to move forward more quickly with new therapies to benefit patients”, said Dr Jonathan Krell, from the Department of Surgery & Cancer at Imperial College London. “We believe that the efficacy of functional TILs retrieved from the Nanoreactor platform shown in our 3D ex-vivo models will generate evidence for a fast track to clinical trials.”
The Nanoreactor platform has been developed by RemedyBio, originating from intellectual property originated at Dublin City University (DCU), following a decade-long R&D programme led Dr. Paul Leonard, the company’s chief scientist and co-founder. The platform has created a step-change in the speed, scale and quality of single cell analysis and discovery, paving the way for powerful new antibodies and cell therapies. Its high-throughput identification capabilities open fresh insights into immune system interactions – driving a new era in precision medicine against cancer and auto-immune disorders.
RemedyBio is a Dublin based biotech company discovering and developing new, patientderived precision and process therapeutics for immuno-oncology and immune disease, by combining the power of ultra-scale single cell analysis and viable recovery in its Nanoreactor™ platform.
The complex biology of the human immune system holds the power to cure major diseases including cancer and immune disease. RemedyBio’s Nanoreactor platform unlocks this complexity, by identifying the therapeutic function of each and every cell, and their interactions in disease situations. With the ability to make the invisible visible in the immune system, RemedyBio is driving a new era in precision therapies, collaborating with leading pharma, biotech and research institutions to deliver safer, more effective and longer lasting treatments to people living with cancer and other major diseases.